Regimen Options for Treatment of Latent TB Infection in HIV-Negative Person

Drug

Regimens

Comments

Daily

Twice Weekly¹

Children

Adults

Children

Adults

Duration

Duration

Duration

Duration

Isoniazid

9 months

9 months

9 months

9 months

Isoniazid

--

6 months

--

6 months

Minimum of 180 doses administered within 9 months

Twice-weekly regimens should consist of at least 52 doses within 9 months.

Recommended regimen for pregnant women

6-month regimen not recommended for those with fibrotic lesions on chest radiographs or children

Contraindicated for persons who have active hepatitis and end-stage liver disease

Rifampin and Pyrazinamide

Not recommended

2 months

Not recommended

2 or 3 months

Minimum of 60 doses to be administered within 3 months

Twice-weekly regimens should consist of at least 16 doses to be administered for 2 months or 24 doses to be administered for 3 months.

May be used for isoniazid-intolerant patients

Avoid PZA for pregnant women because of the risk of adverse effects to the fetus.

This regimen has not been evaluated in HIV-negative persons.

Contraindicated for persons who have active hepatitis and end-stage liver disease

Rifampin

4 months

4 months

Not recommended

Minimum of 120 doses administered within 6 months

For persons who are contacts of patients with INH-resistant, RIF-susceptible TB

May be used for patients who cannot tolerate INH or PZA

Footnotes

INH = isoniazid, RIF = rifampin, RFB = rifabutin, PZA = pyrazinamide, EMB = ethambutol

1. Directly observed treatment of LTBI should be used.